Botulinum toxin-A injections in children with neurogenic bladder

Nephro-Urology Monthly

Volumn 3, Issue 2, 2011, Pages 125-128

  Kroll, Pawel ^a   Jankowski, Andrzej ^a   Soltysiak, Jolanta ^a   Murias, Marek ^a   Skrzypczak, Magdalena ^b   Zachwieja, Jacek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF ANTHROPOLOGY   (Poland)

Author keywords

Botulinum toxin; Neurogenic bladder; Urodynamics

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ARTICLE; BLADDER CAPACITY; BLADDER PRESSURE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; CYSTOSTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; URODYNAMICS;

EID: 79953268330     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Wein AJ. Neuromuscular dysfunction of the lower urinary tract and its treatment. In: Walsh PC, editor. Campbel's Urology. 7th ed. Philadelphia: WB Saunders Company; 1998. p. 953-1006.
2. Frenkl TL, Rackley RR. Injectable neuromodulatory agents: botulinum toxin therapy. Urol Clin North Am. 2005;32(1):89-99.
3. Marte A, Vessella A, Cautiero P, Romano M, Borrelli M, Noviello C, et al. [Efficacy of toxin-A Botulinum for treating intractable bladder hyperactivity in children affected by neuropathic bladder secondary to myelomeningocele: an alternative to enterocystoplasty]. Minerva Pediatr. 2005;57(1):35-40.
4. Verpoorten C, Buyse GM. The neurogenic bladder: medical treatment. Pediatr Nephrol. 2008;23(5):717-25.
5. Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol. 2006;175(3 Pt 1):1102-5.
6. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003;44(2):165-74.
7. Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L, et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol. 2004;171(2 Pt 1):845-8; discussion 8.
8. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. 2003;44(1):139-43.
9. Kuo HC. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology. 2003;61(3):550-4.
10. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174(3):984-9.
11. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol. 2007;52(6):1729-35.
12. Schurch B, Hodler J, Rodic B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry. 1997;63(4):474-6.
13. Gierup J, Ericsson NO, von Hedenberg C. Urodynamic studies in boys with disorders of the lower urinary tract. IV. Congenital bladder neck obstruction. A pre- and postoperative study. Scand J Urol Nephrol. 1978;12(3):195-203.
14. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005;65(1):37-41.